Parmax Pharma Ltd
Incorporated in 1994, Parmax Pharma Ltd manufactures bulk drugs, drugs intermediates, and specialty chemicals[1]
- Market Cap ₹ 16.6 Cr.
- Current Price ₹ 44.4
- High / Low ₹ 55.0 / 25.0
- Stock P/E
- Book Value ₹ -0.27
- Dividend Yield 0.00 %
- ROCE -58.5 %
- ROE -195 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -1.67% over past five years.
- Promoter holding is low: 30.8%
- Company has a low return on equity of -38.9% over last 3 years.
- Debtor days have increased from 29.5 to 60.3 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.89 | 11.99 | 20.92 | 26.17 | 18.24 | 15.39 | 11.02 | 27.64 | |
0.03 | 0.02 | 0.02 | 0.05 | 0.05 | 10.81 | 10.88 | 19.15 | 22.74 | 15.67 | 13.14 | 14.39 | 27.62 | |
Operating Profit | -0.03 | -0.02 | -0.02 | -0.05 | -0.05 | 1.08 | 1.11 | 1.77 | 3.43 | 2.57 | 2.25 | -3.37 | 0.02 |
OPM % | 9.08% | 9.26% | 8.46% | 13.11% | 14.09% | 14.62% | -30.58% | 0.07% | |||||
0.00 | 0.06 | 0.06 | 0.06 | 0.06 | 0.05 | 0.05 | 0.10 | 0.09 | 0.06 | 0.04 | 0.05 | 0.15 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 | 0.13 | 0.37 | 0.39 | 0.37 | 0.62 | 0.51 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09 | 1.03 | 1.01 | 1.94 | 1.93 | 1.88 | 1.71 | 1.62 |
Profit before tax | -0.03 | 0.04 | 0.04 | 0.01 | 0.01 | 0.00 | 0.10 | 0.73 | 1.21 | 0.31 | 0.04 | -5.65 | -1.96 |
Tax % | 0.00% | 0.00% | 25.00% | 200.00% | 100.00% | 20.00% | 41.10% | 38.02% | 54.84% | 375.00% | 2.12% | ||
-0.03 | 0.04 | 0.02 | 0.00 | -0.01 | 0.00 | 0.08 | 0.43 | 0.75 | 0.14 | -0.10 | -5.78 | -2.05 | |
EPS in Rs | -0.08 | 0.10 | 0.05 | 0.00 | -0.03 | 0.00 | 0.21 | 1.15 | 2.00 | 0.37 | -0.27 | -15.45 | -5.48 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -2% |
3 Years: | -25% |
TTM: | 110% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 50% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 4% |
3 Years: | 4% |
1 Year: | 43% |
Return on Equity | |
---|---|
10 Years: | -9% |
5 Years: | -18% |
3 Years: | -39% |
Last Year: | -195% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3.90 | 3.90 | 4.03 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 |
Reserves | 0.06 | 0.09 | 0.12 | 0.11 | 0.10 | 0.11 | 0.18 | 0.61 | 1.37 | 1.51 | 1.40 | -4.38 | -4.55 |
0.90 | 0.92 | 0.79 | 0.46 | 1.02 | 1.96 | 5.52 | 5.26 | 5.89 | 5.18 | 5.37 | 5.91 | 5.75 | |
0.08 | 0.09 | 0.04 | 0.06 | 2.14 | 10.11 | 9.56 | 10.75 | 11.01 | 6.83 | 6.39 | 9.35 | 9.51 | |
Total Liabilities | 4.94 | 5.00 | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 | 15.16 |
2.53 | 2.53 | 2.53 | 2.53 | 2.72 | 5.86 | 4.92 | 9.64 | 10.84 | 10.44 | 9.50 | 9.27 | 8.76 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 1.25 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.20 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 |
2.41 | 2.47 | 2.45 | 2.55 | 4.99 | 10.77 | 11.26 | 11.23 | 11.68 | 7.53 | 8.11 | 5.96 | 5.15 | |
Total Assets | 4.94 | 5.00 | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 | 15.16 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.03 | -0.01 | -0.06 | 0.00 | -0.50 | 3.88 | 0.92 | 2.82 | 3.53 | 0.75 | 0.33 | -0.19 | |
0.00 | 0.00 | 0.00 | 0.00 | -0.19 | -4.23 | -3.41 | -2.40 | -3.15 | -1.53 | -0.94 | -1.59 | |
0.03 | 0.01 | 0.00 | 0.10 | 0.56 | 1.14 | 3.10 | -0.23 | 0.40 | -0.91 | -0.04 | 1.43 | |
Net Cash Flow | 0.00 | 0.00 | -0.06 | 0.09 | -0.14 | 0.79 | 0.61 | 0.20 | 0.78 | -1.69 | -0.65 | -0.35 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 60.48 | 35.01 | 57.58 | 23.01 | 13.61 | 14.70 | 60.28 | |||||
Inventory Days | 203.34 | 278.66 | 88.17 | 107.27 | 154.80 | 286.55 | 123.74 | |||||
Days Payable | 609.39 | 645.07 | 311.84 | 269.40 | 299.82 | 309.82 | 382.60 | |||||
Cash Conversion Cycle | -345.57 | -331.40 | -166.09 | -139.12 | -131.41 | -8.57 | -198.58 | |||||
Working Capital Days | -59.86 | -71.84 | -56.18 | -48.26 | -36.02 | -0.47 | -115.59 | |||||
ROCE % | -0.62% | 0.82% | 0.81% | 0.20% | 0.19% | 0.66% | 1.56% | 8.40% | 14.34% | 6.13% | 3.67% | -58.49% |
Documents
Announcements
-
Board Meeting Intimation for Meeting Of The Board Will Be Held On Friday, 30Th May, 2025 At 4.00 PM Inter Alia To Consider, Approve The Audited Financial Results Of The Quarter And Financial Year Ended On 31St March, 2025
21 May - Board meeting on 30 May 2025 to approve audited results; trading window closed till 48 hours post announcement.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Parmax Pharma confirms it is not classified as Large Corporate per SEBI circular.
-
Compliance Certificate Under Regulation 7(3) Of SEBI (LODR), 2015 For The Year Ended On 31St March, 2025.
21 Apr - Compliance certificate for share transfer activities under SEBI Regulation 7(3) for FY ended March 31, 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
12 Apr - Certificate under Regulation 74(5) for dematerialisation.
- Closure of Trading Window 24 Mar
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
Business Overview:[1]
Company used to do manufacturing bulk drugs and specialty chemicals but it discontinued its business activities for a few years. It deals in active pharmaceutical ingredients and Contract Manufacturing Operations. It plans to extend its activity to the formulation of Tablets, Ointments,
Capsules, and Injectables.